4.6 Article

Update on Anemia in ESRD and Earlier Stages of CKD: Core Curriculum 2018

Journal

AMERICAN JOURNAL OF KIDNEY DISEASES
Volume 71, Issue 3, Pages 423-435

Publisher

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.ajkd.2017.09.026

Keywords

-

Funding

  1. Astra Zeneca
  2. Corvidia
  3. Fibrogen
  4. ZS Pharma
  5. Amgen
  6. Akebia
  7. Pfizer
  8. Keryx
  9. AMAG
  10. Fresenius

Ask authors/readers for more resources

Anemia is a frequent complication during the later stages of chronic kidney disease. When present, it may cause symptoms such as fatigue and shortness of breath. The pathogenesis of anemia in chronic kidney disease is complex, but a central feature is a relative deficit of erythropoietin. New information has elucidated the critical role of the hypoxia-sensing system in mediating erythropoietin synthesis and release. Iron deficiency is a second important factor in the anemia of chronic kidney disease. New insights into the dynamics of iron metabolism have clarified the role of chronic inflammation and hepcidin as key mediators of impaired iron utilization. In this article, we review the epidemiology, pathobiology, clinical evaluation, and treatment of anemia in chronic kidney disease.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available